De novo synthesized large libraries of nucleic acids are provided herein with low error rates. Further, devices for the manufacturing of high-quality building blocks, such as oligonucleotides, are described herein. Longer nucleic acids can be synthesized in parallel using microfluidic assemblies. Further, methods herein allow for the fast construction of large libraries of long, high-quality genes. Devices for the manufacturing of large libraries of long and high-quality nucleic acids are further described herein.

To provide a method for discriminating a microorganism by selecting and using a marker protein capable of reproducibly and quickly discriminating a bacterial species of the genus Listeria. The method for discriminating a microorganism according to the present invention includes: a step of subjecting a sample containing a microorganism to mass spectrometry to obtain a mass spectrum; a reading step of reading a mass-to-charge ratio m/z of a peak derived from a marker protein from the mass spectrum; and a discrimination step of discriminating which bacterial species of Listeria bacteria the microorganism contained in the sample contains based on the mass-to-charge ratio m/z, in which at least one of 17 ribosomal proteins L3, L4, L23, L2, L24, L6, L18, S5, L15, S13, S11, L10, L21, L13, S9, L31, S16 is used as the marker protein and particularly at least one of 8 ribosomal proteins L24, L6, L18, L15, S9, L31, S16 among the 17 ribosomal proteins is used.

Disclosed herein are antibody molecules binding specifically to C-KIT, antigen-binding portions thereof and medical uses therefor.

The purpose of this invention is to provide a method with which it is easy to perform screening for an agent that proliferates or an agent that minimizes the reduction in MCSP-positive basal epidermal stem cells. Provided is a screening method for a laminin 511 expression promoter, which takes the expression of laminin 511 as an indicator. Also provided is an agent for improving skin barrier function, elasticity, hydration and inflammation, said agent including at least one extract selected from among a group consisting of brown algae, red algae and green algae.

An RNA methyltransferase inhibitor comprising sulfonamide-based compounds and/or pyrazoline-based compounds is provided

The present invention provides KOC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

The present invention provides KOC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

The present invention relates to a method for introducing a substance into a plant. The method of the present invention comprises the steps of: obtaining an enzymatically treated and isolated fertilized egg cell by (1-i) isolating a fertilized egg cell from a plant tissue containing a fertilized egg cell, and then treating the fertilized egg cell with an enzyme solution containing a plant tissue-degrading enzyme under a low-titer condition, (1-ii) treating a plant tissue containing a fertilized egg cell with an enzyme solution containing a plant tissue-degrading enzyme under a low-titer condition, and then isolating the fertilized egg cell that has been enzymatically treated, (1-iii) treating a plant tissue containing a fertilized egg cell with an enzyme solution containing a plant tissue-degrading enzyme under a low-titer condition, and simultaneously isolating the fertilized egg cell that has been enzymatically treated, (1-iv) isolating an egg cell and a sperm cell from a plant to produce a fertilized egg by fusing the cells, and then treating the fertilized egg cell with an enzyme solution containing a plant tissue-degrading enzyme under a low-titer condition, or (1-v) treating a plant tissue containing an egg cell with an enzyme solution containing a plant tissue-degrading enzyme under a low-titer condition, and then isolating the egg cell that has been enzymatically treated, and further fusing the egg cell with an isolated sperm cell; and (2) introducing a substance selected from the group consisting of nucleic acids, proteins, and peptides into the resultant enzymatically treated and isolated fertilized egg cell.

An isolated antigen binding protein, which includes at least one CDR of a heavy chain variable region and at least one CDR of a light chain variable region and a method to encode an isolated nucleic acid molecule. A vector with the nucleic acid molecule. A cell with the nucleic acid molecule. A pharmaceutical composition with the isolated antigen binding protein. A method for preventing, alleviating or treating a CS-related disease or disorder. A method for detecting C5 in a sample.

A method for scarless genome editing is disclosed. In particular, the method provides scarless genome modification by using homology directed repair (HDR) steps to genetically modify cells and remove unwanted sequences. This method can be used for genome editing, including introducing mutations, deletions, or insertions at any position in the genome without leaving silent mutations, selection marker sequences, or other additional undesired sequences in the genome.